Dasatinib first-line: Multicentric Italian experience outside clinical trials
详细信息 查看全文
- 作者：Massimo Brecciaa ; breccia@bce.uniroma1.it" class="auth_mail" title="E-mail the corresponding author ; Fabio Stagnot ; Luigiana Lucianou ; Elisabetta Abruzzesev ; Mario Annunziatab ; Mariella D&rsquo ; Addac ; Alessandro Maggid ; Nicola Sgherzae ; Antonella Russo-Rossif ; Patrizia Pregnog ; Fausto Castagnettih ; Alessandra Iurloi ; Roberto Latagliataa ; Michele Cedronej ; Nicola Di Renzok ; Federica Sorà ; l ; Giovanna Rege-Cambrinm ; Giorgio La Nasan ; Anna Rita Scortechinio ; Giovanna Grecop ; Luca Franceschiniq ; Simona Sical ; Monica Bocchiaw ; Monica Crugnolar ; Esther Orlandis ; Attilio Guarinie ; Giorgina Specchiaf ; Gianantonio Rostih ; Giuseppe Sagliom ; Giuliana Alimenaa
- 关键词：Chronic myeloid leukemia ; Dasatinib ; Prognosis
- 刊名：Leukemia Research
- 出版年：2016
- 出版时间：January 2016
- 年：2016
- 卷：40
- 期：Complete
- 页码：24-29
- 全文大小：682 K
文摘
- item" id="list_lis0005">
- •
Dasatinib, a second generation TKI, can be prescribed as frontline treatment.
- •
Lower median age and higher incidence of high Sokal risk were observed in a multicentre population treated outside clinical trials.
- •
Increased rate of molecular responses similar to that reported in sponsored trials.
- •
The results confirmed the low rate of progression.